MeiraGTx Holdings PLC (MGTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $13.25 (+1.53%), Market cap $0.94B, 52-week low–high $4.63 ~ $11.29.
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital a
Financial statements, price targets, institutional (13F) holdings and related news for MeiraGTx Holdings PLC are updated in real time on BlackAll Trade.
MeiraGTx Holdings PLC trades at $13.25 (+1.53%). Real-time quotes and charts are available on BlackAll Trade.
MeiraGTx Holdings PLC has a market cap of about $0.94B.
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, inc